Trial Profile
Calcitonin Gene-Related Peptide Receptor Antagonists for Prevention of Acute Mountain Sickness Prävention der akuten Bergkrankheit durch Calcitonin Gene-Related Peptide Rezeptor Antagonisten
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Erenumab (Primary)
- Indications Altitude sickness
- Focus Adverse reactions
- 13 Jul 2023 New trial record